Peptide class
Both compounds sit in the incretin analogue family, but they are studied for different receptor profiles. Tirzepatide is characterised in the literature as a dual receptor agonist, while retatrutide is described as a triple receptor agonist. Structurally they are distinct synthetic sequences, not variations of one another.
This page is reference information for laboratory personnel handling research materials. It contains no medical, dosing, or human-use guidance of any kind.
Side-by-side reference
- Tirzepatide — dual receptor agonist class; supplied 10 mg, 20 mg, 30 mg; lyophilised powder
- Retatrutide — triple receptor agonist class; supplied 10 mg, 20 mg, 30 mg; lyophilised powder
- Both: white to off-white lyophilised cake in a sealed glass vial
- Both: purity reported by HPLC, identity confirmed by mass spectrometry
- Both: per-lot batch number printed on the label and matched to the certificate of analysis
Handling differences
In practical inventory terms the two behave the same way: both are moisture-sensitive lyophilised powders that should stay sealed, cold, and out of light until they are logged for use. Neither should be stored in a frost-free freezer compartment that cycles temperature aggressively.
The meaningful difference is documentation. Because the two are frequently ordered together, labelling discipline matters — the two vials look alike, and only the printed name, strength, and batch number distinguish them once they leave the outer packaging.
Choosing between them for a study
The selection is driven by the receptor profile the protocol calls for, not by price or availability. Where a protocol specifies a triple agonist, a dual agonist is not a substitute, and the reverse is equally true.
If a comparison is the point of the work, order both from the same supplier and the same shipment where possible, so packaging, transit conditions, and documentation format are consistent across the two arms.
